Vnitr Lek 2009, 55(11):1016-1021

Long-term evaluation of patients with type 1 diabetes mellitus treated with insulin glargine

I. Haladová*, S. Lacigová, D. Čechurová, Z. Jankovec, M. Krčma, Z. Rušavý
Diabetologické centrum I. interní kliniky Lékařské fakulty UK a FN Plzeň, přednosta doc. MUDr. Martin Matějovič, Ph.D.

Aims of the study:
To evaluate long-term effects of treatment with insulin analogue glargine in patients with type 1 diabetes mellitus and to follow up their further course of life. Patient sample and methodology: Retrospective evaluation of 114 patients who, from September 2004, had their basal insulin changed from NPH insulin to insulin glargine. Treatment was changed again in patients in whom a year-long treatment with insulin glargine did not bring improvement in diabetes control. The original sample was divided into 3 groups and the results compared. Compensation of diabetes (HbA1c) after 1, 2 and 3 years and changes to basal and bolus daily insulin dose and body weight were evaluated.

Results: The results are presented as median and 25th and 75th percentile. Group A - 75 patients (65%) treated for the entire evaluation period with insulin glargine. Initial HbA1c was 7.3 (6.4-8.2) %, 6.9 (6.0-8.4) % after 1 year, 7.1 (5.9-7.9) % after 2 years and 6.6 (5.5-7.7) % after 3 years (p < 0.001). We did not identify any statistically significant changes to total, basal or bolus daily dose of insulin or statistically significant body weight increase over the evaluation period. Group B - 19 patients (17%). Switch from insulin glargine to detemir twice daily. Initial HbA1c was 7.3 (6.9-8.5) %, 7.4 (6.8-8.7) % after 1 year of treatment with insulin glargine, 7.7 (7.2-8.1) % before the treatment switch and 7.8 (6.7 - 805) % (NS) after 3 years of treatment. Daily dose of total, basal and bolus insulin did not change and, similarly, no statistically significant change to patients' body weight was identified. Group C - 17 patients (15%). Switch from insulin glargine to an insulin pump. This group had better initial compensation with HbA1c 6.7 (5.7-8.6) %, HbA1c after 1 year was 6.2 (5.6-8.1) %, 7.0 (6.0-7.4) % before the treatment switch and 6.3 (5.2-7.7) % after 3 years of treatment. Total daily insulin dose: 48 (34-60) - 38 (25-49) IU/day (NS). Basal daily insulin dose: 17.5 (13-28) IU/day - 23 (12-32) IU/day (NS). Bolus daily dose decreased significantly: from 25.5 (21-33) to 15.5 (12-22) IU/day (p < 0.01). Body weight: 76 (71-97) kg - 73 (72-99) kg (NS). Only 3% of patients went back to NPH insulin.

Conclusion: Insulin glargine brings improved control of diabetes. The dose of insulin glargine did not differ from NPH insulin. No statistically significant body weight increase was observed during the evaluation period.

Keywords: type 1 diabetes mellitus; diabetes control; insulin glargine

Received: January 16, 2009; Accepted: May 7, 2009; Published: November 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Haladová I, Lacigová S, Čechurová D, Jankovec Z, Krčma M, Rušavý Z. Long-term evaluation of patients with type 1 diabetes mellitus treated with insulin glargine. Vnitr Lek. 2009;55(11):1016-1021.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Green A, Patterson CC. EURODIAB TIGER Study Group. Europe and Diabetes. Trends in the incidence of childhood - onset diabetes in Europe 1989-1998. Diabetologia 2001; 44: (Suppl 3): B3-B8. Go to original source... Go to PubMed...
    2. The Diabetes Control and Complication Trial (DCCT) Research Group. The effect of intensive treatment on the development and progression of long-term comlications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986. Go to original source... Go to PubMed...
    3. Brinchmann-Hansen O, Dahl-Jorgensen K, Sandvik L et al. Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo study. BMJ 1992; 304: 19-22. Go to original source... Go to PubMed...
    4. ČDS. Standardy péče o diabetes mellitus 1. typu. DMEV 2007; 10: 185-188.
    5. The Diabetes Control and Complication Trial Research Group (1993). The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 2006; 329: 977-986. Go to original source...
    6. Ashwell SG, Bradley C, Stephens JW et al. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabetes Care 2008; 31: 1112-1117. Go to original source... Go to PubMed...
    7. Haladová I, Lacigová S, Jankovec Z et al. Klinické zkušenosti s léčbou dlouhodobým inzulinovým analogem glargin v diabetologickém centru. Vnitř Lék 2007; 53: 632-636. Go to PubMed...
    8. Brož J, Kožnarová R, Bartášková D et al. Současné možnosti léčby diabetes mellitus pomocí inzulinových pump. DMEV 2006; 9: 179-186.
    9. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 2005; 19: 178-181. Go to original source... Go to PubMed...
    10. Gough S A. review of human and analogue insulin trials. Diabetes Res Clin Pract 2007; 77: 1-15. Go to original source... Go to PubMed...
    11. Porcellati F, Rossetti P, Pampanelli S et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004; 21: 1213-1220. Go to original source... Go to PubMed...
    12. Gallen I, Carter C. Prospective audit of the introduction of insulin glargine (Lantus) into clinical practice in type 1 diabetes. Pract Diab Int 2004; 21: 110-114. Go to original source...
    13. Kudva YC, Basu A, Jenkins GD al. Randomized controlled clinical trial of glargin versus ultralente insulin in the fragment of type 1 diabetes. Diabetes Care 2005; 28: 10-14. Go to original source... Go to PubMed...
    14. Hirsch IB. Insulin analogues. N Engl J Med 2005; 352: 174-183. Go to original source... Go to PubMed...
    15. Rosenstock J, Park G, Zimmerman J et al. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000; 23: 1137-1142. Go to original source... Go to PubMed...
    16. Alemzadeh R, Berhe T, Wyatt DT. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. Pediatrics 2005; 115: 1320-1324. Go to original source... Go to PubMed...
    17. Murphy NP, Keane SM, Ong KK et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003; 26: 799-804. Go to original source... Go to PubMed...
    18. Ruhnau KJ, Schneider K, Schweitzer MA. Introduction of insulin glargin to basal-bolus therapy improves metabolic control in patients with type 1 diabetes in every day clinical practice. Diabetologia 2005; 48 (Suppl 1): A303.
    19. Chase HP, Arslanian S, White NH et al. Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus. J Pediatr 2008; 153: 547-553. Go to original source... Go to PubMed...
    20. Schütt M, Kern W, Krause U et al. Is the freguency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria. Exp Clin Endocrinol Diabetes 2006; 114: 384-388. Go to original source... Go to PubMed...
    21. Schreiber SA, Russmann A. Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice. Curr Med Res Opin 2007; 23: 3131-3136. Go to original source... Go to PubMed...
    22. Perušičová J. Statistické zpracování průběhu a výsledků léčby inzulinem glargine v ordinaci šesti českých diabetologů. Medicína po promoci 2004; 10-12.
    23. Chase HP, Dixon B, Pearson J et al. Reduced hypoglycaemic episodes and improved glycaemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J Pediatr 2003; 143: 737-740. Go to original source... Go to PubMed...
    24. Owens DR, Griffiths S. Insulin glargine (Lantus). Int J Clin Pract 2002; 56: 460-466. Go to original source... Go to PubMed...
    25. Hamann A, Matthaei S, Rosak C et al. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003; 6: 1738-1744. Go to original source... Go to PubMed...
    26. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148. Go to original source... Go to PubMed...
    27. Pieber TR, Treichel HC, Hompesch B et al. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med 2007; 24: 635-642. Go to original source... Go to PubMed...
    28. Kabadi UM. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus. Clin Drug Investig 2008; 28: 697-701. Go to original source... Go to PubMed...
    29. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. Br Med J 2002; 324: 705. Go to original source... Go to PubMed...
    30. Jeitler K, Horvath K, Berghold A et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008; 51: 941-951. Go to original source... Go to PubMed...
    31. Jankovec Z, Krcma M, Lacigova S et al. National Registry of Patients Treated with Continuous Subcutaneous Insulin Infusion (CSII) in the Czech Republic: Long-term results. Infusystem International 2005; 4: 21-24.
    32. Jankovec Z, Čechurová D, Krčma M et al. Dlouhodobý efekt léčby inzulínovou pumpou (CSII) - výsledky Registru pacientů léčených CSII v České republice. DMEV 2006; 9 (Suppl 2): 26.
    33. Nicolucci A, Maione A, Franciosi M et al. EQuality1 Study Group-Evaluation of QUALITY of Life and Costs in Diabetes Type 1. Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabet Med 2008; 25: 213-220. Go to original source... Go to PubMed...
    34. De Leeuw I, Vague P, Selam JL et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7: 73-82. Go to original source... Go to PubMed...
    35. Bartley PC, Bogoev M, Larsen J et al. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabetic Med 2008; 25: 442-449. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.